Stat4Onc Annual Symposium

项目总结/摘要 癌症是美国第二大死亡原因。统计设计和数据分析方法 在最近开发更有效的癌症治疗方法中发挥了重要作用。虽然成功 像I-SPY 2试验突出的进步，大多数肿瘤学试验没有充分利用强大的 统计创新，肿瘤学家之间仍然缺乏有效的沟通 和统计学家。为了解决这些问题，我们提议召开Stat 4 Onc研讨会， 一个独特的平台，肿瘤学家和统计学家讨论和交流意见， 癌症临床试验、疾病诊断、患者护理和药物决策中的问题 发展本次研讨会将进一步推动统计方法和数据的创新 分析专门用于肿瘤学研究，并将这些创新转化为研究实践。它 也为肿瘤学和统计学的学员提供了一个跨学科学习的场所 合作。研讨会将在四所参与大学之间轮流举行，为期五年， 年融资期。研讨会为期三天，第一天的短期课程与 今年的主题，然后是为期两天的单轨科学计划。这次研讨会 在肿瘤学、统计学、监管和数据科学的科学专门知识方面， 他们的专业协会从学术界（教师，员工和学生），生物制药和 生物技术行业、政府机构和非营利组织，以及性别和种族， 特别是让代表性不足的少数群体参与进来。研讨会的规模将是 大约200名与会者，以便进行充分和有重点的讨论。研讨会将在 单一跟踪以允许参与者参加所有会议。主题演讲和所有会议 将有来自学术界、政府和工业界的演讲者，他们具有肿瘤学方面的专业知识， 统计肿瘤学和统计学学科的学员将获得支持，参加 研讨会，并提供机会，提出在海报和混合会议。专题讨论会 将发表在JCO Precision Oncology和新英格兰数据统计杂志上 科学

Project Summary/Abstract Cancer is the 2nd leading cause of death in US. Statistical designs and data analytics approaches are instrumental in recent development of more effective treatments for cancer. While successes like the I-SPY2 trial highlight the advancement, most oncology trials do not fully utilize powerful statistical innovations and there remains a lack of effective communications between oncologists and statisticians. To address these issues, we propose the Stat4Onc symposium which provides a unique platform for oncologists and statisticians to discuss and exchange ideas for pressing issues in cancer clinical trials, disease diagnosis, patient care, and decision making for drug development. This symposium will further drive innovations in statistical methodology and data analytics dedicated for oncology research and translate these innovations to research practice. It also provides a venue for trainees in oncology and statistics to learn inter-disciplinary collaborations. The symposium will be rotated among the four participating universities in a five- year funding period. The symposium is a three-day event, with first day of short courses relevant to the theme of the year, and then a two-day single-track scientific program. The symposium is inclusive, with respect to scientific expertise in oncology, statistics, regulatory and data sciences, to their professional associations from academia (faculty, staff, and students), biopharma and biotech industry, government agencies, and non-profit organizations, and to gender and ethnicity, in particular for the inclusion of underrepresented minority groups. The symposium size will be around 200 participants, allowing adequate and focused discussions. The symposium will be single tracked to allow participants to be in all the sessions. Keynote talks and all the sessions will have speakers from academic, government, and industry and with expertise in oncology and statistics. Trainees in both oncology and statistics disciplines will be supported for attending the symposium and offers opportunities to present in poster and mixer sessions. Symposium talks will be published in JCO Precision Oncology and New England Journal of Statistics in Data Science.